Control of lung defence by mucins and macrophages: Ancient defence mechanisms with modern functions

European Respiratory Journal

Volumn 48, Issue 4, 2016, Pages 1201-1214

  Janssen, William J ^a,b   Stefanski, Adrianne L ^b   Bochner, Bruce S ^c   Evans, Christopher M ^b  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; CD11B ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD18 ANTIGEN; CD32 ANTIGEN; CD64 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DECTIN 1; FC RECEPTOR; GALECTIN 3; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MUCIN; MUCIN 1; MUCIN 16; MUCIN 4; MUCIN 5AC; MUCIN 5BC; PENTRAXIN 3; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON WILLEBRAND FACTOR; MUC5AC PROTEIN, HUMAN; MUC5B PROTEIN, HUMAN; MUCIN 5B;

ADAPTIVE IMMUNITY; ARTICLE; ASTHMA; CELL FUNCTION; CELLULAR IMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLEMENT SYSTEM; CYSTIC FIBROSIS; ELECTROLYTE TRANSPORT; GENE FUNCTION; GLYCOSYLATION; HUMAN; INNATE IMMUNITY; LEUKOCYTE FUNCTION; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; MACROPHAGE; MUCOCILIARY CLEARANCE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; REGULATORY MECHANISM; SECRETORY CELL; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; CYTOLOGY; HOMEOSTASIS; IMMUNOLOGY; INFLAMMATION; LEUKOCYTE; LUNG; LUNG GAS EXCHANGE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; GLYCOSYLATION; HOMEOSTASIS; HUMANS; INFLAMMATION; LEUKOCYTES; LUNG; MACROPHAGES; MICE; MUCIN 5AC; MUCIN-5B; MUCINS; MUCOCILIARY CLEARANCE; PHAGOCYTOSIS; PULMONARY GAS EXCHANGE;

EID: 84990061986     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00120-2015     Document Type: Article

References (201)

1. O'Connell S, Au-Yeung HK, Gregory CJ, et al. Outdoor and indoor respirable air particulate concentrations in differing urban traffic microenvironments. J Toxicol Environ Health A 2008; 71: 1069-1072.
2. Fromme H. Partikuläre Belastungssituation in Innenräumen, unter besonderer Berücksichtigung von Wohninnenräumen, Gemeinschaftseinrichtungen und Gaststätten [Particulate matter in indoor environmentsexposure situation in residences, schools, pubs, and related recreational spaces]. Gesundheitswesen 2006; 68: 714-723.
3. Kliucininkas L, Martuzevicius D, Krugly E, et al. Indoor and outdoor concentrations of fine particles, particle-bound PAHS and volatile organic compounds in Kaunas, Lithuania. J Environ Monit 2011; 13: 182-191.
4. Guo H, Morawska L, He C, et al. Characterization of particle number concentrations and PM2.5 in a school: influence of outdoor air pollution on indoor air. Environ Sci Pollut Res Int 2010; 17: 1268-1278.
5. Gordon T. Linking health effects to PM components, size, and sources. Inhal Toxicol 2007; 19: Suppl. 1, 3-6.
6. Kappos AD, Bruckmann P, Eikmann T, et al. Health effects of particles in ambient air. Int J Hyg Environ Health 2004; 207: 399-407.
7. Health effects of outdoor air pollution. Part 2. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society. Am J Respir Crit Care Med 1996; 153: 3-50.
8. Kelly FJ, Kelly J. London air quality: a real world experiment in progress. Biomarkers 2009; 14: Suppl. 1, 5-11.
9. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med 2011; 364: 1533-1543.
10. Knowles MR, Daniels LA, Davis SD, et al. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med 2013; 188: 913-922.
11. Button B, Okada SF, Frederick CB, et al. Mechanosensitive ATP release maintains proper mucus hydration of airways. Sci Signal 2013; 6: ra46.
12. Button B, Picher M, Boucher RC. Differential effects of cyclic and constant stress on ATP release and mucociliary transport by human airway epithelia. J Physiol 2007; 580: 577-592.
13. Button B, Cai LH, Ehre C, et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 2012; 337: 937-941.
14. O'Riordan TG, Zwang J, Smaldone GC. Mucociliary clearance in adult asthma. Am Rev Respir Dis 1992; 146: 598-603.
15. Messina MS, O'Riordan TG, Smaldone GC. Changes in mucociliary clearance during acute exacerbations of asthma. Am Rev Respir Dis 1991; 143: 993-997.
16. Foster WM, Langenback EG, Bergofsky EH. Lung mucociliary function in man: interdependence of bronchial and tracheal mucus transport velocities with lung clearance in bronchial asthma and healthy subjects. Ann Occup Hyg 1982; 26: 227-244.
17. Thomas B, Rutman A, Hirst RA, et al. Ciliary dysfunction and ultrastructural abnormalities are features of severe asthma. J Allergy Clin Immunol 2010; 126: 722-729.
18. Moller W, Felten K, Sommerer K, et al. Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery. Am J Respir Crit Care Med 2008; 177: 426-432.
19. Morgan L, Pearson M, de Iongh R, et al. Scintigraphic measurement of tracheal mucus velocity in vivo. Eur Respir J 2004; 23: 518-522.
20. Smaldone GC, Foster WM, O'Riordan TG, et al. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest 1993; 103: 1390-1396.
21. Hasani A, Pavia D, Rotondetto S, et al. Effect of oral antibiotics on lung mucociliary clearance during exacerbation of chronic obstructive pulmonary disease. Respir Med 1998; 92: 442-447.
22. Ordonez CL, Khashayar R, Wong HH, et al. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med 2001; 163: 517-523.
23. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388-395.
24. Innes AL, Woodruff PG, Ferrando RE, et al. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 2006; 130: 1102-1108.
25. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med 2010; 363: 2233-2247.
26. Caramori G, Casolari P, Di Gregorio C, et al. MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. Histopathology 2009; 55: 321-331.
27. Caramori G, Di Gregorio C, Carlstedt I, et al. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology 2004; 45: 477-484.
28. Kirkham S, Kolsum U, Rousseau K, et al. MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178: 1033-1039.
29. Kirkham S, Sheehan JK, Knight D, et al. Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem J 2002; 361: 537-546.
30. Roy MG, Livraghi-Butrico A, Fletcher AA, et al. Muc5b is required for airway defence. Nature 2014; 505: 412-416.
31. Ostrowski LE, Yin W, Rogers TD, et al. Conditional deletion of dnaic1 in a murine model of primary ciliary dyskinesia causes chronic rhinosinusitis. Am J Respir Cell Mol Biol 2010; 43: 55-63.
32. Voronina VA, Takemaru K, Treuting P, et al. Inactivation of Chibby affects function of motile airway cilia. J Cell Biol 2009; 185: 225-233.
33. McKenzie CW, Klonoski JM, Maier T, et al. Enhanced response to pulmonary Streptococcus pneumoniae infection is associated with primary ciliary dyskinesia in mice lacking Pcdp1 and Spef2. Cilia 2013; 2: 18.
34. Nakano Y, Yang IV, Walts AD, et al. MUC5B promoter variant rs35705950 affects MUC5B expression in the distal airways in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016; 193: 464-466.
35. Kamio K, Matsushita I, Hijikata M, et al. Promoter analysis and aberrant expression of the MUC5B gene in diffuse panbronchiolitis. Am J Respir Crit Care Med 2005; 171: 949-957.
36. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364: 1503-1512.
37. Whitsett JA, Alenghat T. Respiratory epithelial cells orchestrate pulmonary innate immunity. Nat Immunol 2015; 16: 27-35.
38. Boucherat O, Boczkowski J, Jeannotte L, et al. Cellular and molecular mechanisms of goblet cell metaplasia in the respiratory airways. Exp Lung Res 2013; 39: 207-216.
39. Evans CM, Koo JS. Airway mucus: the good, the bad, the sticky. Pharmacol Ther 2009; 121: 332-348.
40. Thai P, Loukoianov A, Wachi S, et al. Regulation of airway mucin gene expression. Annu Rev Physiol 2008; 70: 405-429.
41. Voynow JA, Gendler SJ, Rose MC. Regulation of mucin genes in chronic inflammatory airway diseases. Am J Respir Cell Mol Biol 2006; 34: 661-665.
42. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006; 86: 245-278.
43. Tompkins DH, Besnard V, Lange AW, et al. Sox2 is required for maintenance and differentiation of bronchiolar Clara, ciliated, and goblet cells. PloS One 2009; 4: e8248.
44. Reid CJ, Gould S, Harris A. Developmental expression of mucin genes in the human respiratory tract. Am J Respir Cell Mol Biol 1997; 17: 592-598.
45. Buisine MP, Devisme L, Copin MC, et al. Developmental mucin gene expression in the human respiratory tract. Am J Respir Cell Mol Biol 1999; 20: 209-218.
46. Roy MG, Rahmani M, Hernandez JR, et al. Mucin production during prenatal and postnatal murine lung development. Am J Respir Cell Mol Biol 2011; 44: 755-760.
47. Vincent A, Perrais M, Desseyn JL, et al. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene 2007; 26: 6566-6576.
48. Perrais M, Pigny P, Buisine MP, et al. Aberrant expression of human mucin gene MUC5B in gastric carcinoma and cancer cells. Identification and regulation of a distal promoter. J Biol Chem 2001; 276: 15386-15396.
49. Ho JJ, Han SW, Pan PL, et al. Methylation status of promoters and expression of MUC2 and MUC5AC mucins in pancreatic cancer cells. Int J Oncol 2003; 22: 273-279.
50. Yuan S, Hollinger M, Lachowicz-Scroggins ME, et al. Oxidation increases mucin polymer cross-links to stiffen airway mucus gels. Sci Transl Med 2015; 7: 276ra227.
51. Lang T, Hansson GC, Samuelsson T. Gel-forming mucins appeared early in metazoan evolution. Proc Natl Acad Sci USA 2007; 104: 16209-16214.
52. Park SW, Zhen G, Verhaeghe C, et al. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc Natl Acad Sci USA 2009; 106: 6950-6955.
53. Schroeder BW, Verhaeghe C, Park SW, et al. Agr2 is induced in asthma and promotes allergen-induced mucin overproduction. Am J Respir Cell Mol Biol 2012; 47: 178-185.
54. Guo X, Zheng S, Dang H, et al. Genome reference and sequence variation in the large repetitive central exon of human MUC5AC. Am J Respir Cell Mol Biol 2014; 50: 223-232.
55. Johansson ME, Phillipson M, Petersson J, et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci USA 2008; 105: 15064-15069.
56. Johansson ME, Sjovall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol 2013; 10: 352-361.
57. Ambort D, van der Post S, Johansson ME, et al. Function of the CysD domain of the gel-forming MUC2 mucin. Biochem J 2011; 436: 61-70.
58. Nair GB, Ilowite JS. Pharmacologic agents for mucus clearance in bronchiectasis. Clin Chest Med 2012; 33: 363-370.
59. Decramer M, Janssens W. Mucoactive therapy in COPD. Eur Respir Rev 2010; 19: 134-140.
60. Balsamo R, Lanata L, Egan CG. Mucoactive drugs. Eur Respir Rev 2010; 19: 127-133.
61. Shuter J, Hatcher VB, Lowy FD. Staphylococcus aureus binding to human nasal mucin. Infect Immun 1996; 64: 310-318.
62. Scharfman A, Van Brussel E, Houdret N, et al. Interactions between glycoconjugates from human respiratory airways and Pseudomonas aeruginosa. Am J Respir Crit Care Med 1996; 154: S163-S169.
63. Juge N. Microbial adhesins to gastrointestinal mucus. Trends Microbiol 2012; 20: 30-39.
64. Davies J, Carlstedt I, Nilsson AK, et al. Binding of Haemophilus influenzae to purified mucins from the human respiratory tract. Infect Immun 1995; 63: 2485-2492.
65. Trivier D, Houdret N, Courcol RJ, et al. The binding of surface proteins from Staphylococcus aureus to human bronchial mucins. Eur Respir J 1997; 10: 804-810.
66. Linden S, Nordman H, Hedenbro J, et al. Strain- and blood group-dependent binding of Helicobacter pylori to human gastric MUC5AC glycoforms. Gastroenterology 2002; 123: 1923-1930.
67. Linden SK, Wickstrom C, Lindell G, et al. Four modes of adhesion are used during Helicobacter pylori binding to human mucins in the oral and gastric niches. Helicobacter 2008; 13: 81-93.
68. Marionneau S, Airaud F, Bovin NV, et al. Influence of the combined ABO, FUT2, and FUT3 polymorphism on susceptibility to Norwalk virus attachment. J Infect Dis 2005; 192: 1071-1077.
69. Marionneau S, Ruvoen N, Le Moullac-Vaidye B, et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 2002; 122: 1967-1977.
70. Huang P, Farkas T, Marionneau S, et al. Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J Infect Dis 2003; 188: 19-31.
71. Linden S, Semino-Mora C, Liu H, et al. Role of mucin Lewis status in resistance to Helicobacter pylori infection in pediatric patients. Helicobacter 2010; 15: 251-258.
72. Celli JP, Turner BS, Afdhal NH, et al. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci USA 2009; 106: 14321-14326.
73. Kawakubo M, Ito Y, Okimura Y, et al. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science 2004; 305: 1003-1006.
74. Pacheco AR, Curtis MM, Ritchie JM, et al. Fucose sensing regulates bacterial intestinal colonization. Nature 2012; 492: 113-117.
75. Kerr SC, Fischer GJ, Sinha M, et al. Flea expression in Aspergillus fumigatus is recognized by fucosylated structures on mucins and macrophages to prevent lung infection. PLoS Pathogens 2016; 12: e1005555.
76. Okada SF, Zhang L, Kreda SM, et al. Coupled nucleotide and mucin hypersecretion from goblet-cell metaplastic human airway epithelium. Am J Respir Cell Mol Biol 2011; 45: 253-260.
77. Ehre C, Worthington EN, Liesman RM, et al. Overexpressing mouse model demonstrates the protective role of Muc5ac in the lungs. Proc Natl Acad Sci USA 2012; 109: 16528-16533.
78. Corfield AP, Berry M. Glycan variation and evolution in the eukaryotes. Trends Biochem Sci 2015; 40: 351-359.
79. Corfield AP. Mucins: a biologically relevant glycan barrier in mucosal protection. Biochim Biophys Acta 2015; 1850: 236-252.
80. Hanisch FG, Bonar D, Schloerer N, et al. Human trefoil factor 2 is a lectin that binds alpha-GlcNAc-capped mucin glycans with antibiotic activity against Helicobacter pylori. J Biol Chem 2014; 289: 27363-27375.
81. Tan L, Psaltis A, Baker LM, et al. Aberrant mucin glycoprotein patterns of chronic rhinosinusitis patients with bacterial biofilms. Am J Rhinol Allergy 2010; 24: 319-324.
82. Magalhaes A, Gomes J, Ismail MN, et al. Fut2-null mice display an altered glycosylation profile and impaired baba-mediated Helicobacter pylori adhesion to gastric mucosa. Glycobiology 2009; 19: 1525-1536.
83. Mata M, Sarrion I, Armengot M, et al. Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine. PloS One 2012; 7: e48037.
84. Oshansky CM, Pickens JA, Bradley KC, et al. Avian influenza viruses infect primary human bronchial epithelial cells unconstrained by sialic acid alpha2, 3 residues. PloS One 2011; 6: e21183.
85. Lachowicz-Scroggins ME, Boushey HA, Finkbeiner WE, et al. Interleukin-13-induced mucous metaplasia increases susceptibility of human airway epithelium to rhinovirus infection. Am J Respir Cell Mol Biol 2010; 43: 652-661.
86. Pittet LA, Hall-Stoodley L, Rutkowski MR, et al. Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae. Am J Respir Cell Mol Biol 2010; 42: 450-460.
87. Winter C, Herrler G, Neumann U. Infection of the tracheal epithelium by infectious bronchitis virus is sialic acid dependent. Microbes Infect 2008; 10: 367-373.
88. Wu CA, Peluso JJ, Shanley JD, et al. Murine cytomegalovirus influences Foxj1 expression, ciliogenesis, and mucus plugging in mice with allergic airway disease. Am J Pathol 2008; 172: 714-724.
89. Thompson CI, Barclay WS, Zambon MC, et al. Infection of human airway epithelium by human and avian strains of influenza A virus. J Virol 2006; 80: 8060-8068.
90. Huang T, You Y, Spoor MS, et al. Foxj1 is required for apical localization of ezrin in airway epithelial cells. J Cell Sci 2003; 116: 4935-4945.
91. Look DC, Walter MJ, Williamson MR, et al. Effects of paramyxoviral infection on airway epithelial cell Foxj1 expression, ciliogenesis, and mucociliary function. Am J Pathol 2001; 159: 2055-2069.
92. Zaynagetdinov R, Sherrill TP, Kendall PL, et al. Identification of myeloid cell subsets in murine lungs using flow cytometry. Am J Respir Cell Mol Biol 2013; 49: 180-189.
93. Desch AN, Gibbings SL, Goyal R, et al. Flow cytometric analysis of mononuclear phagocytes in nondiseased human lung and lung-draining lymph nodes. Am J Respir Crit Care Med 2016; 193: 614-626.
94. Heron M, Grutters JC, ten Dam-Molenkamp KM, et al. Bronchoalveolar lavage cell pattern from healthy human lung. Clin Exp Immunol 2012; 167: 523-531.
95. Lensmar C, Elmberger G, Sandgren P, et al. Leukocyte counts and macrophage phenotypes in induced sputum and bronchoalveolar lavage fluid from normal subjects. Eur Respir J 1998; 12: 595-600.
96. Hashimoto D, Chow A, Noizat C, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013; 38: 792-804.
97. Guilliams M, De Kleer I, Henri S, et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J Exp Med 2013; 210: 1977-1992.
98. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity 2014; 41: 21-35.
99. Coggle JE, Tarling JD. The proliferation kinetics of pulmonary alveolar macrophages. J Leukoc Biol 1984; 35: 317-327.
100. Tarling JD, Coggle JE. Evidence for the pulmonary origin of alveolar macrophages. Cell Tissue Kinet 1982; 15: 577-584.
101. Sawyer RT. The significance of local resident pulmonary alveolar macrophage proliferation to population renewal. J Leukoc Biol 1986; 39: 77-87.
102. Jenkins SJ, Ruckerl D, Cook PC, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011; 332: 1284-1288.
103. Janssen WJ, Barthel L, Muldrow A, et al. Fas determines differential fates of resident and recruited macrophages during resolution of acute lung injury. Am J Respir Crit Care Med 2011; 184: 547-560.
104. Thepen T, Van Rooijen N, Kraal G. Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. J Exp Med 1989; 170: 499-509.
105. Thepen T, Hoeben K, Breve J, et al. Alveolar macrophages down-regulate local pulmonary immune responses against intratracheally administered T-cell-dependent, but not T-cell-independent antigens. Immunology 1992; 76: 60-64.
106. Bang BR, Chun E, Shim EJ, et al. Alveolar macrophages modulate allergic inflammation in a murine model of asthma. Exp Mol Med 2011; 43: 275-280.
107. Kooguchi K, Hashimoto S, Kobayashi A, et al. Role of alveolar macrophages in initiation and regulation of inflammation in Pseudomonas aeruginosa pneumonia. Infect Immun 1998; 66: 3164-3169.
108. Holt PG. Down-regulation of immune responses in the lower respiratory tract: the role of alveolar macrophages. Clin Exp Immunol 1986; 63: 261-270.
109. Zaslona Z, Przybranowski S, Wilke C, et al. Resident alveolar macrophages suppress, whereas recruited monocytes promote, allergic lung inflammation in murine models of asthma. J Immunol 2014; 193: 4245-4253.
110. Broug-Holub E, Toews GB, van Iwaarden JF, et al. Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect Immun 1997; 65: 1139-1146.
111. Machado-Aranda D, V Suresh M, Yu B, et al. Alveolar macrophage depletion increases the severity of acute inflammation following nonlethal unilateral lung contusion in mice. J Trauma Acute Care Surg 2014; 76: 982-990.
112. Elder A, Johnston C, Gelein R, et al. Lung inflammation induced by endotoxin is enhanced in rats depleted of alveolar macrophages with aerosolized clodronate. Exp Lung Res 2005; 31: 527-546.
113. Qiu H, KuoLee R, Harris G, et al. Role of macrophages in early host resistance to respiratory Acinetobacter baumannii infection. PloS One 2012; 7: e40019.
114. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003; 422: 37-44.
115. Kumari S, Mg S, Mayor S. Endocytosis unplugged: multiple ways to enter the cell. Cell Res 2010; 20: 256-275.
116. Doyle SE, O'Connell RM, Miranda GA, et al. Toll-like receptors induce a phagocytic gene program through p38. J Exp Med 2004; 199: 81-90.
117. Blander JM, Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science 2004; 304: 1014-1018.
118. Kong L, Ge BX. Myd88-independent activation of a novel actin-Cdc42/Rac pathway is required for Toll-like receptor-stimulated phagocytosis. Cell Res 2008; 18: 745-755.
119. Kotlar HK, Harbitz O, Jenssen AO, et al. Quantitation of proteins in sputum from patients with chronic obstructive lung disease. II. Determination of albumin, transferrin, alpha1-acid glycoprotein, IgG, IgM, lysozyme and C3-complement factor. Eur J Respir Dis 1980; 61: 233-239.
120. Hill SL, Mitchell JL, Burnett D, et al. IgG subclasses in the serum and sputum from patients with bronchiectasis. Thorax 1998; 53: 463-468.
121. Sloane AJ, Lindner RA, Prasad SS, et al. Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. Am J Respir Crit Care Med 2005; 172: 1416-1426.
122. Aitken ML, Greene KE, Tonelli MR, et al. Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis. Chest 2003; 123: 792-799.
123. Wright SM, Hockey PM, Enhorning G, et al. Altered airway surfactant phospholipid composition and reduced lung function in asthma. J Appl Physiol (1985) 2000; 89: 1283-1292.
124. Shimura S, Masuda T, Takishima T, et al. Surfactant apoprotein-A concentration in airway secretions for the detection of pulmonary oedema. Eur Respir J 1996; 9: 2525-2530.
125. Masuda T, Shimura S, Sasaki H, et al. Surfactant apoprotein-A concentration in sputum for diagnosis of pulmonary alveolar proteinosis. Lancet 1991; 337: 580-582.
126. Peebles RS Jr, Liu MC, Lichtenstein LM, et al. IgA, IgG and IgM quantification in bronchoalveolar lavage fluids from allergic rhinitics, allergic asthmatics, and normal subjects by monoclonal antibody-based immunoenzymetric assays. J Immunol Methods 1995; 179: 77-86.
127. Sato T, Kitajima A, Ohmoto S, et al. Determination of human immunoglobulin A and secretory immunoglobulin A in bronchoalveolar lavage fluids by solid phase enzyme immunoassay. Clin Chim Acta 1993; 220: 145-156.
128. Bakema JE, van Egmond M. The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol 2011; 4: 612-624.
129. Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25: 21-50.
130. Wolfert MA, Boons G-J. Adaptive immune activation: glycosylation does matter. Nat Chem Biol 2013; 9: 776-784.
131. Crook CK, Lipsitt LP. Neonatal nutritive sucking: effects of taste stimulation upon sucking rhythm and heart rate. Child Dev 1976; 47: 518-522.
132. Pelaseyed T, Bergstrom JH, Gustafsson JK, et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev 2014; 260: 8-20.
133. Watford WT, Ghio AJ, Wright JR. Complement-mediated host defense in the lung. Am J Physiol Lung Cell Mol Physiol 2000; 279: L790-L798.
134. Reynolds HY, Newball HH. Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med 1974; 84: 559-573.
135. Robertson J, Caldwell JR, Castle JR, et al. Evidence for the presence of components of the alternative (properdin) pathway of complement activation in respiratory secretions. J Immunol 1976; 117: 900-903.
136. Nayak A, Ferluga J, Tsolaki AG, et al. The non-classical functions of the classical complement pathway recognition subcomponent c1q. Immunol Lett 2010; 131: 139-150.
137. Nayak A, Pednekar L, Reid KB, et al. Complement and non-complement activating functions of c1q: a prototypical innate immune molecule. Innate Immun 2012; 18: 350-363.
138. Ehlers MR. Cr3: a general purpose adhesion-recognition receptor essential for innate immunity. Microbes Infect 2000; 2: 289-294.
139. Gasque P. Complement: a unique innate immune sensor for danger signals. Mol Immunol 2004; 41: 1089-1098.
140. Ross GD, Cain JA, Lachmann PJ. Membrane complement receptor type three (Cr3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. J Immunol 1985; 134: 3307-3315.
141. Thornton BP, Vetvicka V, Pitman M, et al. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 1996; 156: 1235-1246.
142. Troelstra A, de Graaf-Miltenburg LA, van Bommel T, et al. Lipopolysaccharide-coated erythrocytes activate human neutrophils via CD14 while subsequent binding is through CD11b/CD18. J Immunol 1999; 162: 4220-4225.
143. Sutterwala FS, Rosenthal LA, Mosser DM. Cooperation between CR1 (CD35) and CR3 (CD11b/CD18) in the binding of complement-opsonized particles. J Leukoc Biol 1996; 59: 883-890.
144. van Egmond M, van Vuuren AJ, Morton HC, et al. Human immunoglobulin a receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18). Blood 1999; 93: 4387-4394.
145. Rijneveld AW, de Vos AF, Florquin S, et al. CD11b limits bacterial outgrowth and dissemination during murine pneumococcal pneumonia. J Infect Dis 2005; 191: 1755-1760.
146. Agramonte-Hevia J, Gonzalez-Arenas A, Barrera D, et al. Gram-negative bacteria and phagocytic cell interaction mediated by complement receptor 3. FEMS Immunol Med Microbiol 2002; 34: 255-266.
147. Humbles AA, Lu B, Nilsson CA, et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000; 406: 998-1001.
148. Wu J, Kobayashi M, Sousa EA, et al. Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following segmental antigen challenge. Mol Cellular Proteomics 2005; 4: 1251-1264.
149. Dillard P, Wetsel RA, Drouin SM. Complement C3a regulates Muc5ac expression by airway Clara cells independently of Th2 responses. Am J Respir Crit Care Med 2007; 175: 1250-1258.
150. Zelensky AN, Gready JE. The C-type lectin-like domain superfamily. FEBS J 2005; 272: 6179-6217.
151. Kishore U, Greenhough TJ, Waters P, et al. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol 2006; 43: 1293-1315.
152. Kuronuma K, Sano H, Kato K, et al. Pulmonary surfactant protein A augments the phagocytosis of Streptococcus pneumoniae by alveolar macrophages through a casein kinase 2-dependent increase of cell surface localization of scavenger receptor A. J Biol Chem 2004; 279: 21421-21430.
153. Watford WT, Smithers MB, Frank MM, et al. Surfactant protein A enhances the phagocytosis of C1q-coated particles by alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2002; 283: L1011-L1022.
154. Gil M, McCormack FX, Levine AM. Surfactant protein A modulates cell surface expression of CR3 on alveolar macrophages and enhances CR3-mediated phagocytosis. J Biol Chem 2009; 284: 7495-7504.
155. Beharka AA, Crowther JE, McCormack FX, et al. Pulmonary surfactant protein A activates a phosphatidylinositol 3-kinase/calcium signal transduction pathway in human macrophages: participation in the up-regulation of mannose receptor activity. J Immunol 2005; 175: 2227-2236.
156. Beharka AA, Gaynor CD, Kang BK, et al. Pulmonary surfactant protein A up-regulates activity of the mannose receptor, a pattern recognition receptor expressed on human macrophages. J Immunol 2002; 169: 3565-3573.
157. Kudo K, Sano H, Takahashi H, et al. Pulmonary collectins enhance phagocytosis of Mycobacterium avium through increased activity of mannose receptor. J Immunol 2004; 172: 7592-7602.
158. Kerrigan AM, Brown GD. C-type lectins and phagocytosis. Immunobiology 2009; 214: 562-575.
159. Le Cabec V, Emorine LJ, Toesca I, et al. The human macrophage mannose receptor is not a professional phagocytic receptor. J Leukoc Biol 2005; 77: 934-943.
160. Brown GD, Taylor PR, Reid DM, et al. Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 2002; 196: 407-412.
161. Brown GD, Herre J, Williams DL, et al. Dectin-1 mediates the biological effects of beta-glucans. J Exp Med 2003; 197: 1119-1124.
162. Brown GD, Gordon S. Immune recognition. A new receptor for beta-glucans. Nature 2001; 413: 36-37.
163. Diniz SN, Nomizo R, Cisalpino PS, et al. PTX3 function as an opsonin for the dectin-1-dependent internalization of zymosan by macrophages. J Leukoc Biol 2004; 75: 649-656.
164. Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. Vaccine 2015; 33: Suppl. 4, D60-D65.
165. Schwitzguebel AJ, Jandus P, Lacroix JS, et al. Immunoglobulin deficiency in patients with chronic rhinosinusitis: systematic review of the literature and meta-analysis. J Allergy Clin Immunol 2015; 136: 1523-1531.
166. Gathmann B, Mahlaoui N, Gerard L, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 2014; 134: 116-126.
167. Oksenhendler E, Gerard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008; 46: 1547-1554.
168. Kainulainen L, Suonpaa J, Nikoskelainen J, et al. Bacteria and viruses in maxillary sinuses of patients with primary hypogammaglobulinemia. Arch Otolaryngol Head Neck Surg 2007; 133: 597-602.
169. Busse PJ, Farzan S, Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Ann Allergy Asthma Immunol 2007; 98: 1-8; quiz 8-11, 43.
170. Kainulainen L, Varpula M, Liippo K, et al. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol 1999; 104: 1031-1036.
171. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92: 34-48.
172. Fitzpatrick AM, Holguin F, Teague WG, et al. Alveolar macrophage phagocytosis is impaired in children with poorly controlled asthma. J Allergy Clin Immunol 2008; 121: 1372-1378.
173. Berenson CS, Garlipp MA, Grove LJ, et al. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis 2006; 194: 1375-1384.
174. Taylor AE, Finney-Hayward TK, Quint JK, et al. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J 2010; 35: 1039-1047.
175. Marti-Lliteras P, Regueiro V, Morey P, et al. Nontypeable Haemophilus influenzae clearance by alveolar macrophages is impaired by exposure to cigarette smoke. Infect Immun 2009; 77: 4232-4242.
176. Berenson CS, Kruzel RL, Eberhardt E, et al. Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. J Infect Dis 2013; 208: 2036-2045.
177. Alexis NE, Soukup J, Nierkens S, et al. Association between airway hyperreactivity and bronchial macrophage dysfunction in individuals with mild asthma. Am J Physiol Lung Cell Mol Physiol 2001; 280: L369-L375.
178. Donnelly LE, Barnes PJ. Defective phagocytosis in airways disease. Chest 2012; 141: 1055-1062.
179. Lehnert BE. Pulmonary and thoracic macrophage subpopulations and clearance of particles from the lung. Environ Health Perspect 1992; 97: 17-46.
180. Lehnert BE, Valdez YE, Sebring RJ, et al. Airway intra-luminal macrophages: evidence of origin and comparisons to alveolar macrophages. Am J Respir Cell Mol Biol 1990; 3: 377-391.
181. Lehnert BE, Morrow PE. Association of 59-iron oxide with alveolar macrophages during alveolar clearance. Exp Lung Res 1985; 9: 1-16.
182. Lehnert BE, Valdez YE, Holland LM. Pulmonary macrophages: alveolar and interstitial populations. Exp Lung Res 1985; 9: 177-190.
183. Warheit DB, Hill LH, Brody AR. Surface morphology and correlated phagocytic capacity of pulmonary macrophages lavaged from the lungs of rats. Exp Lung Res 1984; 6: 71-82.
184. Yeh HC, Schum GM, Duggan MT. Anatomic models of the tracheobronchial and pulmonary regions of the rat. Anat Rec 1979; 195: 483-492.
185. Sorokin SP, Brain JD. Pathways of clearance in mouse lungs exposed to iron oxide aerosols. Anat Rec 1975; 181: 581-625.
186. Westphalen K, Gusarova GA, Islam MN, et al. Sessile alveolar macrophages communicate with alveolar epithelium to modulate immunity. Nature 2014; 506: 503-506.
187. Shan M, Gentile M, Yeiser JR, et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science 2013; 342: 447-453.
188. McDole JR, Wheeler LW, McDonald KG, et al. Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine. Nature 2012; 483: 345-349.
189. Patnode ML, Cheng CW, Chou CC, et al. Galactose-6-O-sulfotransferases are not required for the generation of Siglec-F ligands in leukocytes or lung tissue. J Biol Chem 2013; 288: 26533-26545.
190. Kiwamoto T, Katoh T, Evans CM, et al. Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis. J Allergy Clin Immunol 2015; 135: 1329-1340.
191. Mao H, Kano G, Hudson SA, et al. Mechanisms of Siglec-F-induced eosinophil apoptosis: a role for caspases but not for SHP-1, Src kinases, NADPH oxidase or reactive oxygen. PloS One 2013; 8: e68143.
192. Zimmermann N, McBride ML, Yamada Y, et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy 2008; 63: 1156-1163.
193. Song DJ, Cho JY, Lee SY, et al. Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling. J Immunol 2009; 183: 5333-5341.
194. Guo JP, Myers AC, Choi O, et al. Ligands for Siglec-8 and Siglec-F: binding characteristics and tissue distribution. J Allergy Clin Immunol 119: S299.
195. Kiwamoto T, Brummet ME, Wu F, et al. Mice deficient in the St3gal3 gene product α2, 3 sialyltransferase (ST3Gal-III) exhibit enhanced allergic eosinophilic airway inflammation. J Allergy Clin Immunol 2014; 133: 240-247.
196. Suzukawa M, Miller M, Rosenthal P, et al. Sialyltransferase ST3Gal-III regulates Siglec-F ligand formation and eosinophilic lung inflammation in mice. J Immunol 2013; 190: 5939-5948.
197. Zhang M, Angata T, Cho JY, et al. Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 2007; 109: 4280-4287.
198. Cho JY, Song DJ, Pham A, et al. Chronic ova allergen challenged Siglec-F deficient mice have increased mucus, remodeling, and epithelial Siglec-F ligands which are up-regulated by IL-4 and IL-13. Respir Res 2010; 11: 154.
199. Jia Y, Yu H, Fernandes SM, et al. Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells. J Allergy Clin Immunol 2015; 135: 799-810.
200. Kano G, Almanan M, Bochner BS, et al. Mechanism of Siglec-8-mediated cell death in IL-5-activated eosinophils: role for reactive oxygen species-enhanced MEK/ERK activation. J Allergy Clin Immunol 2013; 132: 437-445.
201. Nutku E, Aizawa H, Hudson SA, et al. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003; 101: 5014-5020.